Blueprint Medicines (BPMC)
(Real Time Quote from BATS)
$103.88 USD
+0.01 (0.01%)
Updated Jun 18, 2024 10:06 AM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 481 - 500 ( 513 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q4 Financials; Expansion Cohorts on Track; Multiple Data Points in 2017, Reiterate OUTPERFORM and $43 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Early BLU-285 Data in Systemic Mastocytosis Look Favorable Relative to Competition
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Proof of Concept for BLU-285 in GIST Reported at ENA; Reiterate OUTPERFORM and Raising PT to $43 (from $41)
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-554 Shows Benefit in Advanced HCC Patients, Including Those With FGF19 Overexpression
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-554 Abstract Reports Early Proof of Concept for Targeting FGFR4, Reiterate OUTPERFORM and $41 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials; Early Activity for BLU-285 in SM Patients; GIST and BLU-554 data at "Triple" Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials; Early Activity for BLU-285 in SM Patients; GIST and BLU-554 data at "Triple" Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BPMC Data Preview Ahead of Preliminary Ph 1 Data Readouts
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 10
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q2 EPS; Important Data Readouts from Three Ph 1 Studies Ahead, Reiterate OUTPERFORM and $41 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q1 EPS; BLU-554 and BLU-285 Dose Escalations Continue, Preliminary Data Updates Expected YE:16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D